Received Jul 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4n222 | IM |
received Priorix IM instead of SC; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 23-year-old female patient who received MMR (Priorix) (batch number 4n222, expiry date 13-SEP-2026) for prophylaxis. On 15-APR-2025, the patient received Priorix (intramuscular use). On 15-APR-2025, an unknown time after receiving Priorix, the patient experienced intramuscular formulation administered by other route (Verbatim: received Priorix IM instead of SC). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-JUN-2025 The patient received Priorix intramuscularly instead of subcutaneous, which led intramuscular formulation administered by other route. The reporter consented to follow up.